Evidence map›Paper›PMID 39219843›Full record

ArticleBioinformatics advances2024

Gregor Rot, Arne Wehling, Roland Schmucki, Nikolaos Berntenis, Jitao David Zhang, Martin Ebeling

Abstract read
In one paragraph

Article in Bioinformatics advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Gregor RotRoche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.ORCID https://orcid.org/0009-0001-7888-6687
Arne WehlingRoche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.ORCID https://orcid.org/0000-0002-0845-626X
Roland SchmuckiRoche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Nikolaos BerntenisRoche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Jitao David ZhangRoche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.ORCID https://orcid.org/0000-0002-3085-0909
Martin EbelingRoche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Motivation: Analysis of alternative splicing using short-read RNA-seq data is a complex process that involves several steps: alignment of reads to the reference genome, identification of alternatively spliced features, motif discovery, analysis of RNA-protein binding near donor and acceptor splice sites, and exploratory data visualization. To the best of our knowledge, there is currently no integrative open-source software dedicated to this task. Results: Here, we introduce Availability and implementation: The software

Identifiers

PMID39219843
PMCPMC11364168

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.